TSE:ASP

Acerus Pharmaceuticals (ASP) Stock Price, News & Analysis

Acerus Pharmaceuticals logo

About Acerus Pharmaceuticals Stock (TSE:ASP)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
1,250 shs
Average Volume
4,719 shs
Market Capitalization
C$2.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Receive ASP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ASP Stock News Headlines

Acerus Update
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
IIROC Trading Halt - ASP
Acerus Files For CCAA Protection
Acerus: Q3 Earnings Snapshot
See More Headlines

ASP Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Acerus Pharmaceuticals investors own include Acerus Pharmaceuticals (TRLPF), Absolute Software Co. (ABT.TO) (ABT), Aurora Cannabis (ACB), Frontera Energy (PRE), Trilogy International Partners (TRL), Ability (ABIL).

Industry, Sector and Symbol

Stock Exchange
TSE
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
TSE:ASP
CIK
N/A
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
C($4.41)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-C$28.08 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-54.10%

Debt

Debt-to-Equity Ratio
261.01
Current Ratio
0.67
Quick Ratio
0.26

Sales & Book Value

Annual Sales
C$3.04 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
3.29
Book Value
C($1.80) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
7,710,000
Free Float
N/A
Market Cap
C$2.78 million
Optionable
Not Optionable
Beta
1.03
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (TSE:ASP) was last updated on 1/26/2023 by MarketBeat.com Staff.
From Our Partners